id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-0861-0006,FDA,FDA-2025-E-0861,Determination of Regulatory Review Period for Purposes of Patent Extension; GRAFAPEX,Notice,Determinations,2025-12-10T05:00:00Z,2025,12,2025-12-10T05:00:00Z,2026-02-10T04:59:59Z,2025-12-10T20:10:46Z,2025-22382,0,0,09000064b90c15e6
FDA-2025-E-0861-0005,FDA,FDA-2025-E-0861,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-08-27T04:00:00Z,2025,8,2025-08-27T04:00:00Z,,2025-08-27T22:24:38Z,,0,0,09000064b8f1b7fa
FDA-2025-E-0861-0004,FDA,FDA-2025-E-0861,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-07-15T04:00:00Z,2025,7,2025-07-15T04:00:00Z,,2025-07-15T19:43:11Z,,0,0,09000064b8e6f0dc
FDA-2025-E-0861-0003,FDA,FDA-2025-E-0861,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2025-06-30T04:00:00Z,2025,6,2025-06-30T04:00:00Z,,2025-06-30T20:16:26Z,,0,0,09000064b8e43512
FDA-2025-E-0861-0002,FDA,FDA-2025-E-0861,"Patent Extension Application from Greenblum & Bernstein, P.L.C. (on behalf of Medac Gesellschaft fur Klinische Spezialpraparate mbH)",Other,Application,2025-03-26T04:00:00Z,2025,3,2025-03-26T04:00:00Z,,2025-03-26T11:40:51Z,,0,0,0900006486a293f4
FDA-2025-E-0861-0001,FDA,FDA-2025-E-0861,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-03-26T04:00:00Z,2025,3,2025-03-26T04:00:00Z,,2025-03-26T11:40:43Z,,0,0,0900006486a293f2